Global Human Microbiome Based Drugs and Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Human Microbiome Based Drugs and Diagnostics market size was valued at USD 851.9 million in 2023 and is forecast to a readjusted size of USD 1647 million by 2030 with a CAGR of 9.9% during review period.

The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Human Microbiome Based Drugs and Diagnostics industry chain, the market status of Clinical Research Institutes (Therapeutics, Diagnostics), Hospital (Therapeutics, Diagnostics), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Human Microbiome Based Drugs and Diagnostics.

Regionally, the report analyzes the Human Microbiome Based Drugs and Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Human Microbiome Based Drugs and Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Human Microbiome Based Drugs and Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Human Microbiome Based Drugs and Diagnostics industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Therapeutics, Diagnostics).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Human Microbiome Based Drugs and Diagnostics market.

Regional Analysis: The report involves examining the Human Microbiome Based Drugs and Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Human Microbiome Based Drugs and Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Human Microbiome Based Drugs and Diagnostics:
Company Analysis: Report covers individual Human Microbiome Based Drugs and Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Human Microbiome Based Drugs and Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Clinical Research Institutes, Hospital).

Technology Analysis: Report covers specific technologies relevant to Human Microbiome Based Drugs and Diagnostics. It assesses the current state, advancements, and potential future developments in Human Microbiome Based Drugs and Diagnostics areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Human Microbiome Based Drugs and Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Human Microbiome Based Drugs and Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Therapeutics
    Diagnostics

Market segment by Application
    Clinical Research Institutes
    Hospital
    Surgical Centers
    Others

Market segment by players, this report covers
    Second Genome
    Enterome Bioscience
    Yakult
    Dowdupont
    Vedanta BioSciences
    Metabiomics Corporation
    ViThera Pharmaceuticals
    MicroBiome Therapeutics
    Osel
    Merck

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Human Microbiome Based Drugs and Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Human Microbiome Based Drugs and Diagnostics, with revenue, gross margin and global market share of Human Microbiome Based Drugs and Diagnostics from 2019 to 2024.
Chapter 3, the Human Microbiome Based Drugs and Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Human Microbiome Based Drugs and Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human Microbiome Based Drugs and Diagnostics.
Chapter 13, to describe Human Microbiome Based Drugs and Diagnostics research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Human Microbiome Based Drugs and Diagnostics
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Human Microbiome Based Drugs and Diagnostics by Type
        1.3.1 Overview: Global Human Microbiome Based Drugs and Diagnostics Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type in 2023
        1.3.3 Therapeutics
        1.3.4 Diagnostics
    1.4 Global Human Microbiome Based Drugs and Diagnostics Market by Application
        1.4.1 Overview: Global Human Microbiome Based Drugs and Diagnostics Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Clinical Research Institutes
        1.4.3 Hospital
        1.4.4 Surgical Centers
        1.4.5 Others
    1.5 Global Human Microbiome Based Drugs and Diagnostics Market Size & Forecast
    1.6 Global Human Microbiome Based Drugs and Diagnostics Market Size and Forecast by Region
        1.6.1 Global Human Microbiome Based Drugs and Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Human Microbiome Based Drugs and Diagnostics Market Size by Region, (2019-2030)
        1.6.3 North America Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2019-2030)
        1.6.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2019-2030)
        1.6.6 South America Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Second Genome
        2.1.1 Second Genome Details
        2.1.2 Second Genome Major Business
        2.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.1.4 Second Genome Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Second Genome Recent Developments and Future Plans
    2.2 Enterome Bioscience
        2.2.1 Enterome Bioscience Details
        2.2.2 Enterome Bioscience Major Business
        2.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.2.4 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Enterome Bioscience Recent Developments and Future Plans
    2.3 Yakult
        2.3.1 Yakult Details
        2.3.2 Yakult Major Business
        2.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.3.4 Yakult Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Yakult Recent Developments and Future Plans
    2.4 Dowdupont
        2.4.1 Dowdupont Details
        2.4.2 Dowdupont Major Business
        2.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.4.4 Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Dowdupont Recent Developments and Future Plans
    2.5 Vedanta BioSciences
        2.5.1 Vedanta BioSciences Details
        2.5.2 Vedanta BioSciences Major Business
        2.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.5.4 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Vedanta BioSciences Recent Developments and Future Plans
    2.6 Metabiomics Corporation
        2.6.1 Metabiomics Corporation Details
        2.6.2 Metabiomics Corporation Major Business
        2.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.6.4 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Metabiomics Corporation Recent Developments and Future Plans
    2.7 ViThera Pharmaceuticals
        2.7.1 ViThera Pharmaceuticals Details
        2.7.2 ViThera Pharmaceuticals Major Business
        2.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.7.4 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 ViThera Pharmaceuticals Recent Developments and Future Plans
    2.8 MicroBiome Therapeutics
        2.8.1 MicroBiome Therapeutics Details
        2.8.2 MicroBiome Therapeutics Major Business
        2.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.8.4 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 MicroBiome Therapeutics Recent Developments and Future Plans
    2.9 Osel
        2.9.1 Osel Details
        2.9.2 Osel Major Business
        2.9.3 Osel Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.9.4 Osel Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Osel Recent Developments and Future Plans
    2.10 Merck
        2.10.1 Merck Details
        2.10.2 Merck Major Business
        2.10.3 Merck Human Microbiome Based Drugs and Diagnostics Product and Solutions
        2.10.4 Merck Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Merck Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Human Microbiome Based Drugs and Diagnostics Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Human Microbiome Based Drugs and Diagnostics by Company Revenue
        3.2.2 Top 3 Human Microbiome Based Drugs and Diagnostics Players Market Share in 2023
        3.2.3 Top 6 Human Microbiome Based Drugs and Diagnostics Players Market Share in 2023
    3.3 Human Microbiome Based Drugs and Diagnostics Market: Overall Company Footprint Analysis
        3.3.1 Human Microbiome Based Drugs and Diagnostics Market: Region Footprint
        3.3.2 Human Microbiome Based Drugs and Diagnostics Market: Company Product Type Footprint
        3.3.3 Human Microbiome Based Drugs and Diagnostics Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Human Microbiome Based Drugs and Diagnostics Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2024)
    5.2 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2030)
    6.2 North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2030)
    6.3 North America Human Microbiome Based Drugs and Diagnostics Market Size by Country
        6.3.1 North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2030)
        6.3.2 United States Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        6.3.3 Canada Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        6.3.4 Mexico Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2030)
    7.2 Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2030)
    7.3 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country
        7.3.1 Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2030)
        7.3.2 Germany Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        7.3.3 France Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        7.3.5 Russia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        7.3.6 Italy Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region
        8.3.1 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2019-2030)
        8.3.2 China Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        8.3.3 Japan Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        8.3.4 South Korea Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        8.3.5 India Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        8.3.7 Australia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2030)
    9.2 South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2030)
    9.3 South America Human Microbiome Based Drugs and Diagnostics Market Size by Country
        9.3.1 South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2030)
        9.3.2 Brazil Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        9.3.3 Argentina Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country
        10.3.1 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2030)
        10.3.2 Turkey Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)
        10.3.4 UAE Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Human Microbiome Based Drugs and Diagnostics Market Drivers
    11.2 Human Microbiome Based Drugs and Diagnostics Market Restraints
    11.3 Human Microbiome Based Drugs and Diagnostics Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Human Microbiome Based Drugs and Diagnostics Industry Chain
    12.2 Human Microbiome Based Drugs and Diagnostics Upstream Analysis
    12.3 Human Microbiome Based Drugs and Diagnostics Midstream Analysis
    12.4 Human Microbiome Based Drugs and Diagnostics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Second Genome Company Information, Head Office, and Major Competitors
    Table 6. Second Genome Major Business
    Table 7. Second Genome Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 8. Second Genome Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Second Genome Recent Developments and Future Plans
    Table 10. Enterome Bioscience Company Information, Head Office, and Major Competitors
    Table 11. Enterome Bioscience Major Business
    Table 12. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 13. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Enterome Bioscience Recent Developments and Future Plans
    Table 15. Yakult Company Information, Head Office, and Major Competitors
    Table 16. Yakult Major Business
    Table 17. Yakult Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 18. Yakult Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Yakult Recent Developments and Future Plans
    Table 20. Dowdupont Company Information, Head Office, and Major Competitors
    Table 21. Dowdupont Major Business
    Table 22. Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 23. Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Dowdupont Recent Developments and Future Plans
    Table 25. Vedanta BioSciences Company Information, Head Office, and Major Competitors
    Table 26. Vedanta BioSciences Major Business
    Table 27. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 28. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Vedanta BioSciences Recent Developments and Future Plans
    Table 30. Metabiomics Corporation Company Information, Head Office, and Major Competitors
    Table 31. Metabiomics Corporation Major Business
    Table 32. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 33. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. Metabiomics Corporation Recent Developments and Future Plans
    Table 35. ViThera Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 36. ViThera Pharmaceuticals Major Business
    Table 37. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 38. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. ViThera Pharmaceuticals Recent Developments and Future Plans
    Table 40. MicroBiome Therapeutics Company Information, Head Office, and Major Competitors
    Table 41. MicroBiome Therapeutics Major Business
    Table 42. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 43. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. MicroBiome Therapeutics Recent Developments and Future Plans
    Table 45. Osel Company Information, Head Office, and Major Competitors
    Table 46. Osel Major Business
    Table 47. Osel Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 48. Osel Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Osel Recent Developments and Future Plans
    Table 50. Merck Company Information, Head Office, and Major Competitors
    Table 51. Merck Major Business
    Table 52. Merck Human Microbiome Based Drugs and Diagnostics Product and Solutions
    Table 53. Merck Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Merck Recent Developments and Future Plans
    Table 55. Global Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) by Players (2019-2024)
    Table 56. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Players (2019-2024)
    Table 57. Breakdown of Human Microbiome Based Drugs and Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 58. Market Position of Players in Human Microbiome Based Drugs and Diagnostics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 59. Head Office of Key Human Microbiome Based Drugs and Diagnostics Players
    Table 60. Human Microbiome Based Drugs and Diagnostics Market: Company Product Type Footprint
    Table 61. Human Microbiome Based Drugs and Diagnostics Market: Company Product Application Footprint
    Table 62. Human Microbiome Based Drugs and Diagnostics New Market Entrants and Barriers to Market Entry
    Table 63. Human Microbiome Based Drugs and Diagnostics Mergers, Acquisition, Agreements, and Collaborations
    Table 64. Global Human Microbiome Based Drugs and Diagnostics Consumption Value (USD Million) by Type (2019-2024)
    Table 65. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Share by Type (2019-2024)
    Table 66. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Forecast by Type (2025-2030)
    Table 67. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024)
    Table 68. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Forecast by Application (2025-2030)
    Table 69. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 70. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 71. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 72. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 73. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 74. North America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 75. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 76. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 77. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 78. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 79. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 80. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 81. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 82. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 83. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 84. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 85. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2019-2024) & (USD Million)
    Table 86. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2025-2030) & (USD Million)
    Table 87. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 88. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 89. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 90. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 91. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 92. South America Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 93. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 94. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 95. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 96. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 97. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 98. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 99. Human Microbiome Based Drugs and Diagnostics Raw Material
    Table 100. Key Suppliers of Human Microbiome Based Drugs and Diagnostics Raw Materials
List of Figures
    Figure 1. Human Microbiome Based Drugs and Diagnostics Picture
    Figure 2. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type in 2023
    Figure 4. Therapeutics
    Figure 5. Diagnostics
    Figure 6. Global Human Microbiome Based Drugs and Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 7. Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application in 2023
    Figure 8. Clinical Research Institutes Picture
    Figure 9. Hospital Picture
    Figure 10. Surgical Centers Picture
    Figure 11. Others Picture
    Figure 12. Global Human Microbiome Based Drugs and Diagnostics Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Human Microbiome Based Drugs and Diagnostics Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market Human Microbiome Based Drugs and Diagnostics Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Region in 2023
    Figure 17. North America Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Players in 2023
    Figure 23. Human Microbiome Based Drugs and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players Human Microbiome Based Drugs and Diagnostics Market Share in 2023
    Figure 25. Global Top 6 Players Human Microbiome Based Drugs and Diagnostics Market Share in 2023
    Figure 26. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Share by Type (2019-2024)
    Figure 27. Global Human Microbiome Based Drugs and Diagnostics Market Share Forecast by Type (2025-2030)
    Figure 28. Global Human Microbiome Based Drugs and Diagnostics Consumption Value Share by Application (2019-2024)
    Figure 29. Global Human Microbiome Based Drugs and Diagnostics Market Share Forecast by Application (2025-2030)
    Figure 30. North America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 40. France Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Region (2019-2030)
    Figure 47. China Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 50. India Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE Human Microbiome Based Drugs and Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 64. Human Microbiome Based Drugs and Diagnostics Market Drivers
    Figure 65. Human Microbiome Based Drugs and Diagnostics Market Restraints
    Figure 66. Human Microbiome Based Drugs and Diagnostics Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Human Microbiome Based Drugs and Diagnostics in 2023
    Figure 69. Manufacturing Process Analysis of Human Microbiome Based Drugs and Diagnostics
    Figure 70. Human Microbiome Based Drugs and Diagnostics Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Companies Mentioned

Second Genome
Enterome Bioscience
Yakult
Dowdupont
Vedanta BioSciences
Metabiomics Corporation
ViThera Pharmaceuticals
MicroBiome Therapeutics
Osel
Merck